Dr. Geoffrey M. Nichol M.D. serves as Independent Director of the Company. He was appointed to our Board in December 2019. Dr. Nichol has nearly 30 years' experience in drug development. He has served as Chief Medical Officer at BioMarin Pharmaceutical Inc., where he manages an active portfolio of clinical development programs, since November 2016. From July 2011 to November 2016, he was Executive Vice President, Research and Development at Sangamo BioSciences, where he managed the preclinical development of several IND candidates. From September 2002 to January 2010, he was Senior Vice President of Development at Medarex, where he was responsible for a portfolio of clinical development programs. From February 1996 to September 2002, he was Vice President at Novartis, where he managed a clinical development therapeutic area, United States Medical Affairs, and Global Project and Portfolio Management. From December 1989 to February 1996, he held various positions up to Group Medical Director, Clinical Development at SmithKline Beecham, where he was responsible for anti-infective development and medical affairs. Dr. Nichol received a B.Med.Sc., M.B., Ch.B., or the equivalent of an M.D. in the U.S., from Otago University Medical School in New Zealand and an M.B.A. from Warwick University in the United Kingdom. Nichol's extensive experience in the pharmaceutical and biotechnology industry qualifies him to serve on our Board.
Geoffrey Nichol is 65, he's been the Independent Director of Millendo Therapeutics since 2019. There are 1 older and 13 younger executives at Millendo Therapeutics. The oldest executive at Millendo Therapeutics, Inc. is John Howe, 77, who is the Independent Director.
Geoffrey's mailing address filed with the SEC is C/O MILLENDO THERAPEUTICS, INC., 110 MILLER AVENUE, SUITE 100, ANN ARBOR, MI, 48104.
Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.
Millendo Therapeutics executives and other stock owners filed with the SEC include: